Interventional News’ popular stories last month included acquisitions by Boston Scientific and Gore, studies of deep vein thrombosis and peripheral arterial disease treatments and, on the subject of the latter, research into the racial disparities affecting patients who receive peripheral vascular interventions. Stories covering data presented at two of the summer’s meetings—Society of Interventional Radiology (SIR) and the European Conference on Embolotherapy (ET)—also garnered ample views.
Boston Scientific has announced the acquisition of Obsidio, a privately held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature.
Inari Medical has announced planned enrolment of the DEFIANCE randomised controlled trial (RCT), which is designed to compare the clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the ClotTriever system versus anticoagulation only.
BD has announced the start of enrolment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB). The PREVISION trial is a prospective, multicentre, single arm, non-randomised study designed to evaluate the safety of the BD sirolimus DCB in the treatment of peripheral arterial disease (PAD) in the femoropopliteal arteries.
Fluidx Medical disclosed study results examining extent of vessel filling using the GPX embolic device compared to microspheres, a common treatment for many types of tumours.
A database study titled ‘Unplanned 30-day readmissions and in-hospital outcomes for the management of submassive and massive acute pulmonary embolism: Catheter-directed versus systemic thrombolysis’ has produced results that could provide some of the evidence base for preference of catheter-directed over systemic thrombolysis in treating the more severe cases of pulmonary embolism (PE).
Mark Little (Royal Berkshire NHS Foundation Trust, Reading, UK) described the emergence of, and advancement within, musculoskeletal (MSK) embolotherapy as “fast-paced” during a presentation at this year’s ET (22–25 June, Nice, France). The take-home message was that the “signs are encouraging” when it comes to MSK embolotherapy’s integration into more mainstream practice.
Ramona Gupta (Northwestern University, Chicago, USA) addresses the issue of recurrent varicose veins, highlighting in particular the “multiple tools” now at physicians’ disposal to treat the problem.
Gore has announced the acquisition of InnAVasc Medical, a privately held medical technology company focused on advancing care for patients with end-stage renal disease who utilise graft circuits for dialysis treatment.
Interventional News spoke to Eric A Secemsky and Anna K Krawisz (Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, USA)—about the motivations for carrying out their study into racial disparities in peripheral vascular interventions, the results it yielded, and where this research might lead.
Concept Medical has announced the initiation of the LIMES trial, which has enrolled 15 patients to evaluate the safety and efficacy of the company’s Magic Touch sirolimus-coated percutaneous transluminal angioplasty (PTA) balloon for the treatment of peripheral arterial disease (PAD).